Varicella-Zoster Immune Globulin (Human)
- Atc Codes:J06BB03
Table of contents
- Brand Names
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
Canada: Varizig; USA: Varicella-Zoster Immune Globulin (Human).
Latin America
Argentina: Varitect.
Drug combinations
Chemistry
Pharmacologic Category
Serums, Toxoids, and Vaccines; Serums. Immune Globulin. (ATC-Code: J06BB03).
Mechanism of action
Antibodies obtained from pooled human plasma of individuals with high titers of varicella-zoster provide passive immunity.
Therapeutic use
Prevention or reduction in severity of maternal infection within 4 days of exposure to varicella zoster virus, in pregnant women.
Pregnancy and lactiation implications
Animal reproduction studies not conducted. Clinical use of other immunoglobulins suggests that there are no adverse effects on fetus. Use with caution in nursing women.
Unlabeled use
Contraindications
Severe reaction associated with past human immune globulin administration. Hypersensitivity to any component of the formulation. Patients with evidence of immunity. IgA deficiency.
Warnings and precautions
Hypersensitivity and anaphylactic reactions can occur. Noncardiogenic pulmonary edema reported with intravenous administration of immune globulin (use caution with pre-existing respiratory conditions). Acute renal dysfunction (increased serum creatinine, oliguria, acute renal failure) can rarely occur (use with caution in the elderly, renal disease, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications due to risk of renal dysfunction). Thrombotic events reported with administration of intravenous immune globulin (use with caution in cardiovascular risk factors). Product of human plasma; may potentially contain infectious agents which could transmit disease.